Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Severe COVID-19 Pneumonia
NCT04535063Phase 3Completed
- Sponsor
- CEMIC
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of COVID-19 convalescent plasma in COVID-19 pneumonia, sponsored by CEMIC. Primary endpoint: 28 days survival. Started Apr 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04535063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535063.